Recruiting OBSERVATIONAL NCT06691061
The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis
Real-life Comparative Effectiveness of Vedolizumab, Ustekinumab and JAK Inhibitors in Patients with Ulcerative Colitis After Anti-TNFα Failure or Intolerance
Sponsor: Humanitas Clinical and Research Center
Conditions
Ulcerative Colitis (Disorder)
Interventions
JAK Inhibitor Ustekinumab - Standard Dosage Vedolizumab
Updated 1 time since 2024 Last updated: Nov 14, 2024 Started: Aug 1, 2023 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06691061, this observational or N/A phase trial focuses on Ulcerative Colitis (Disorder) and remains actively recruiting participants. Sponsored by Humanitas Clinical and Research Center, it has been updated 1 time since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Humanitas Clinical and Research Center
Data source: Humanitas Clinical and Research Center
For direct contact, visit the study record on ClinicalTrials.gov .